Adakveo (crizanlizumab-tmca) is an intravenous humanized monoclonal antibody that binds to P-selectin. P-selectin is an adhesion molecule expressed on vascular endothelial cells and platelets and is a key modulator in the vaso-occlusive process. The inhibition of P-selectin is believed to reduce sickle red blood cell adhesion, thereby improving blood flow and minimizing vaso-occlusive crises in patients with sickle cell disease.

If you have a Hayes login, click here to view the full report on the Knowledge Center.